Medicare’s plan to roll back broad telehealth coverage starting January 31, 2026 has pushed Teladoc Health (TDOC) into the spotlight, as investors weigh regulatory risk alongside a sharp pickup in bullish options trading.

The Medicare headlines and analyst concerns have landed on a stock that was already under pressure, with a 7 day share price return of a 13.9% decline and a 1 year total shareholder return of a 46.36% decline. Recent options activity hints at investors reassessing both risk and potential catalysts around upcoming earnings.

If this kind of regulatory and earnings driven volatility has your attention, it could be a good moment to scan other virtual care names and the broader healthcare stocks for ideas beyond Teladoc Health.

With Teladoc Health trading at US$5.45, a value score of 5, and both intrinsic and analyst implied discounts above 60%, are investors looking at a beaten down virtual care platform on sale, or is the market already bracing for weaker future growth?

Most Popular Narrative: 40.3% Undervalued

With Teladoc Health last closing at $5.45 against a narrative fair value of $9.13, the gap between price and story is hard to ignore.

Teladoc's continued investment in product innovation including enhanced cardiometabolic programs and integrated mental health offerings positions the company to capture growing demand for digital management of chronic diseases and leverage the increasing need for cost-effective care, supporting long-term revenue and enrollment growth.

Want the full playbook behind that fair value? The narrative focuses on steady revenue expansion, a very different profit margin profile, and a re-rated earnings multiple. Curious which assumptions carry the biggest weight in that equation?

Result: Fair Value of $9.13 (UNDERVALUED)

However, the story could change quickly if BetterHelp’s shift toward lower margin insurance revenue drags on earnings or if Medicare’s telehealth reset hits virtual visit volumes.

Build Your Own Teladoc Health Narrative

If you look at this data and reach a different conclusion, or prefer to test your own assumptions, you can build a custom view in a few minutes with Do it your way.

A great starting point for your Teladoc Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Teladoc has you rethinking your watchlist, this is a good time to widen your search and see what other opportunities the Simply Wall St Screener surfaces.

• Hunt for potential high risk, high reward names by scanning these 3528 penny stocks with strong financials that already show stronger balance sheets and income statements than many expect from this corner of the market.
• Target the intersection of healthcare and artificial intelligence by reviewing these 111 healthcare AI stocks where software, data and clinical outcomes come together in listed companies.
• Zero in on possible value ideas by filtering for these 872 undervalued stocks based on cash flows that screen well on discounted cash flow metrics and might deserve a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.